Expert Interview
Getting a fresh look at Ocular's axitinib ahead of its wet amd phase 3 data readout.
Ticker(s): OCULInstitution: Stanford
Professor of Ophthalmology at the Byers Eye Institute, Stanford University School of Medicine, specializing in retinal vascular diseases, uveitis, and ocular inflammatory disorders.
Serves as principal investigator on landmark NIH- and industry-sponsored trials for neovascular AMD, diabetic macular edema, and uveitis, previously holding leadership roles at Johns Hopkins, University of Nebraska Medical Center, and Truhlsen Eye Institute.
Leads pioneering first-in-human and proof-of-concept studies that contributed to the FDA approval of aflibercept and ranibizumab, with over 300 publications and inaugural Editor-in-Chief of American Journal of Ophthalmology Case Reports.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
